Gyre Therapeutics, Inc. (GYRE) stock
Close on Nov 18, 2026Market cap $483.95MP/E –Yield –
Earnings
Gyre Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Gyre Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 11, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | $32.90M | +7.5% | -$0.04 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 7, 2026before the open | $29.10M | +8.6% | -$0.12 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026after the close | $22.50M | +1.8% | -$0.10 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 12, 2026after the close | $37.20M | +33.3% | -$0.02 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 7, 2025after the close | $30.60M | +20.0% | $0.03 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 11, 2025during market hours | $26.80M | +6.3% | $0.00 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 9, 2025after the close | $22.10M | -18.8% | $0.00 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 17, 2025during market hours | $27.90M | – | $0.00 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 13, 2024during market hours | $25.50M | – | $0.01 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 13, 2024after the close | $25.20M | – | $0.01 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024during market hours | $27.20M | – | $0.03 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 26, 2024after the close | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023before the open | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022during market hours | – | – | $1.64 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022during market hours | $794.00K | – | -$0.46 | Release |
| Q4 FY2021ended Dec 31, 2021 | Apr 5, 2022during market hours | – | – | -$0.65 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 12, 2021before the open | $2.30M | – | -$0.80 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Jan 26, 2021during market hours | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 6, 2020during market hours | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 11, 2020during market hours | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Feb 14, 2020during market hours | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Nov 7, 2019before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Gyre Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| revenue | FY2026 | $100.50M – $111.00M | $100.50M – $111.00M | Reaffirmed | May 7, 2026 |
| revenue guidance | FY2026 | $100.50M – $111.00M | $100.50M – $111.00M | Reaffirmed | Nov 5, 2026 |
Guidance vs results
The last range Gyre Therapeutics gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $115.00M – $118.00M | $116.70MΣ4Q | Within range |
Guidance history
Every forecast Gyre Therapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | revenue guidance | FY2026 | $100.50M – $111.00M | Reaffirmed |
| Aug 7, 2026 | revenue | FY2026 | $100.50M – $111.00M | New |
| May 7, 2026 | revenue | FY2026 | $100.50M – $111.00M | Reaffirmed |
| Mar 12, 2026 | revenues | FY2026 | $100.50M – $111.00M | New |
| Nov 7, 2025 | revenue guidance | FY2025 | $115.00M – $118.00M | New |
| Aug 11, 2025 | growth over 2024 revenue | FY2025 | +11.3% – +20.8% | Lowered |
| Aug 11, 2025 | revenues | FY2025 | $118.00M – $128.00M | Reaffirmed |
| May 9, 2025 | revenue guidance | FY2025 | $118.00M – $128.00M | Reaffirmed |
| Mar 17, 2025 | revenues | FY2025 | $118.00M – $128.00M | New |
| Feb 18, 2025 | Operating profit | FY2025 | 23,217 | New |
| Feb 18, 2025 | Basic earnings per share | FY2025 | 240.42 | New |
| Feb 18, 2025 | Revenue | FY2025 | 28,733 | New |
| Feb 18, 2025 | Revenue % | FY2025 | +21.7% | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Gyre Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Update
- Results
- Results
- Update
- Update
- Update
- Results
- Update
- Results
- Update
See a number that looks wrong?